TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:49
AVADEL PHARMACEUTICALS PLC ( AVDL ) https://www.avadel.com
10.61USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-27.28%
AVDL
SPY
32.66%
AVDL
32.96%
SPY
108.59%
AVDL
45.74%
SPY
302.52%
-39.58%
AVDL
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1021.74
957.88
0.63
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-14.08
7.40
13.68
-6.85
0.00
-26.33
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-0.65
87.70
-21.56
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.3616
-51.59
-38.50
1.37
Other Earnings and Cash Flow Stats:
AVADEL PHARMACEUTICALS PLC ( AVDL ) Net Income TTM ($MM) is -72.58
AVADEL PHARMACEUTICALS PLC ( AVDL ) Operating Income TTM ($MM) is -64.00
AVADEL PHARMACEUTICALS PLC ( AVDL ) Owners' Earnings Annual ($MM) is 0.00
AVADEL PHARMACEUTICALS PLC ( AVDL ) Current Price to Owners' Earnings ratio is 0.00
AVADEL PHARMACEUTICALS PLC ( AVDL ) EBITDA TTM ($MM) is -62.01
AVADEL PHARMACEUTICALS PLC ( AVDL ) EBITDA Margin is -21.56%
Capital Allocation:
AVADEL PHARMACEUTICALS PLC ( AVDL ) has paid 0.00 dividends per share and bought back -6.92 million shares in the past 12 months
AVADEL PHARMACEUTICALS PLC ( AVDL ) has reduced its debt by 0.903 million USD in the last 12 months
Capital Structure:
AVADEL PHARMACEUTICALS PLC ( AVDL ) Interest-bearing Debt ($MM) as of last quarter is 1
AVADEL PHARMACEUTICALS PLC ( AVDL ) Annual Working Capital Investments ($MM) are 14
AVADEL PHARMACEUTICALS PLC ( AVDL ) Book Value ($MM) as of last quarter is 74
AVADEL PHARMACEUTICALS PLC ( AVDL ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
AVADEL PHARMACEUTICALS PLC ( AVDL ) has 28 million in cash on hand as of last quarter
AVADEL PHARMACEUTICALS PLC ( AVDL ) has 42 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AVADEL PHARMACEUTICALS PLC ( AVDL ) has 96 common shares outstanding as of last quarter
AVADEL PHARMACEUTICALS PLC ( AVDL ) has 0 million USD of preferred stock value
Academic Scores:
AVADEL PHARMACEUTICALS PLC ( AVDL ) Altman Z-Score is 1.24 as of last quarter
AVADEL PHARMACEUTICALS PLC ( AVDL ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
AVADEL PHARMACEUTICALS PLC ( AVDL ) largest shareholder is owning shares at 0.00 ($MM) value
MCHUGH THOMAS S(an insider) Bought 2300 shares of AVADEL PHARMACEUTICALS PLC ( AVDL ) for the amount of $24018.67 on 2024-12-13
4.77% of AVADEL PHARMACEUTICALS PLC ( AVDL ) is held by insiders, and 80.00% is held by institutions
AVADEL PHARMACEUTICALS PLC ( AVDL ) went public on 1996-06-07
Other AVADEL PHARMACEUTICALS PLC ( AVDL ) financial metrics:
FCF:-83.72
Unlevered Free Cash Flow:0.00
EPS:-0.11
Operating Margin:-0.65
Gross Profit Margin:87.70
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-14.06
Beta:1.37
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AVADEL PHARMACEUTICALS PLC ( AVDL ) :
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.